Ignite Creation Date:
2025-12-25 @ 2:20 AM
Ignite Modification Date:
2025-12-28 @ 12:04 AM
Study NCT ID:
NCT05950334
Status:
COMPLETED
Last Update Posted:
2025-08-22
First Post:
2023-07-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Sponsor:
Fate Therapeutics
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
FT522-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None